Dualitybio and Genentech collaborate on DUPAC-based ADCs

Dualitybio Inc. has entered into a collaboration and license agreement with Genentech Inc., a member of the Roche Group, to develop next-generation antibody-drug conjugates (ADCs) built on the company’s proprietary DUPAC (Dualitybio Unique Payload Antibody Conjugate) platform.